Rescue of Severely Affected Dystrophin/utrophin-deficient Mice Through ScAAV-U7snRNA-mediated Exon Skipping

Overview

Journal Hum Mol Genet

Specialties Genetics
Molecular Biology

Date 2012 Mar 6

PMID 22388933

Citations 56

Authors

Aurelie Goyenvalle

Arran Babbs

Jordan Wright

Vivienne Wilkins

Dave Powell

Luis Garcia

Kay E Davies

Affiliations

Soon will be listed here.

Abstract

Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dystrophin gene that result in the absence of functional protein. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD and recent clinical trials have demonstrated encouraging results. However, antisense oligonucleotide-mediated exon skipping for DMD still faces major hurdles such as extremely low efficacy in the cardiac muscle, poor cellular uptake and relatively rapid clearance from circulation, which means that repeated administrations are required to achieve some therapeutic efficacy. To overcome these limitations, we previously proposed the use of small nuclear RNAs (snRNAs), especially U7snRNA to shuttle the antisense sequences after vectorization into adeno-associated virus (AAV) vectors. In this study, we report for the first time the efficiency of the AAV-mediated exon skipping approach in the utrophin/dystrophin double-knockout (dKO) mouse which is a very severe and progressive mouse model of DMD. Following a single intravenous injection of scAAV9-U7ex23 in dKO mice, near-normal levels of dystrophin expression were restored in all muscles examined, including the heart. This resulted in a considerable improvement of their muscle function and dystrophic pathology as well as a remarkable extension of the dKO mice lifespan. These findings suggest great potential for AAV-U7 in systemic treatment of the DMD phenotype.

Citing Articles

Targeting EP2 Receptor Improves Muscle and Bone Health in Dystrophin/Utrophin Double-Knockout Mice.

Gao X, Cui Y, Zhang G, Ruzbarsky J, Wang B, Layne J Cells. 2025; 14(2).

PMID: 39851544 PMC: 11763967. DOI: 10.3390/cells14020116.

Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.

Ogieuhi I, Callender K, Odukudu G, Obi E, Muzofa K, Babalola A High Blood Press Cardiovasc Prev. 2024; 32(1):33-47.

PMID: 39476283 DOI: 10.1007/s40292-024-00682-w.

Design and evaluation of antisense sequence length for modified mouse U7 small nuclear RNA to induce efficient pre-messenger RNA splicing modulation in vitro.

Shimo T, Ueda O, Yamamoto S PLoS One. 2024; 19(7):e0305012.

PMID: 38980892 PMC: 11232981. DOI: 10.1371/journal.pone.0305012.

EV-mediated promotion of myogenic differentiation is dependent on dose, collection medium, and isolation method.

Hanson B, Vorobieva I, Zheng W, Conceicao M, Lomonosova Y, Mager I Mol Ther Nucleic Acids. 2023; 33:511-528.

PMID: 37602275 PMC: 10432918. DOI: 10.1016/j.omtn.2023.07.005.

Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mice.

Saoudi A, Barberat S, Le Coz O, Vacca O, Doisy Caquant M, Tensorer T Mol Ther Nucleic Acids. 2023; 32:173-188.

PMID: 37078061 PMC: 10106732. DOI: 10.1016/j.omtn.2023.03.009.

References

Bish L, Morine K, Sleeper M, Sanmiguel J, Wu D, Gao G . Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008; 19(12):1359-68. PMC: 2940566. DOI: 10.1089/hum.2008.123. View

Yin H, Moulton H, Seow Y, Boyd C, Boutilier J, Iverson P . Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet. 2008; 17(24):3909-18. PMC: 7108561. DOI: 10.1093/hmg/ddn293. View

Wu B, Moulton H, Iversen P, Jiang J, Li J, Li J . Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A. 2008; 105(39):14814-9. PMC: 2546441. DOI: 10.1073/pnas.0805676105. View

Zincarelli C, Soltys S, Rengo G, Koch W, Rabinowitz J . Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci. 2010; 3(3):81-9. PMC: 3962265. DOI: 10.1111/j.1752-8062.2010.00190.x. View

Koenig M, Beggs A, Moyer M, Scherpf S, Heindrich K, Bettecken T . The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989; 45(4):498-506. PMC: 1683519. View

Malerba A, Sharp P, Graham I, Arechavala-Gomeza V, Foster K, Muntoni F . Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther. 2010; 19(2):345-54. PMC: 3034854. DOI: 10.1038/mt.2010.261. View

Crisp A, Yin H, Goyenvalle A, Betts C, Moulton H, Seow Y . Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet. 2010; 20(3):413-21. DOI: 10.1093/hmg/ddq477. View

Goemans N, Tulinius M, van den Akker J, Burm B, Ekhart P, Heuvelmans N . Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med. 2011; 364(16):1513-22. DOI: 10.1056/NEJMoa1011367. View

Mingozzi F, High K . Immune responses to AAV in clinical trials. Curr Gene Ther. 2007; 7(5):316-24. DOI: 10.2174/156652307782151425. View

10.

Mingozzi F, Hasbrouck N, Basner-Tschakarjan E, Edmonson S, Hui D, Sabatino D . Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007; 110(7):2334-41. PMC: 1988950. DOI: 10.1182/blood-2007-03-080093. View

11.

Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran T . Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther. 2009; 17(1):132-40. DOI: 10.1038/gt.2009.120. View

12.

Wang Z, Storb R, Lee D, Kushmerick M, Chu B, Berger C . Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther. 2009; 18(3):617-24. PMC: 2839426. DOI: 10.1038/mt.2009.294. View

13.

Mingozzi F, Maus M, Hui D, Sabatino D, Murphy S, Rasko J . CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007; 13(4):419-22. DOI: 10.1038/nm1549. View

14.

Grady R, Teng H, Nichol M, Cunningham J, WILKINSON R, Sanes J . Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 1997; 90(4):729-38. DOI: 10.1016/s0092-8674(00)80533-4. View

15.

Lu Q, Rabinowitz A, Chen Y, Yokota T, Yin H, Alter J . Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A. 2004; 102(1):198-203. PMC: 544058. DOI: 10.1073/pnas.0406700102. View

16.

Goyenvalle A, Wright J, Babbs A, Wilkins V, Garcia L, Davies K . Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther. 2012; 20(6):1212-21. PMC: 3369406. DOI: 10.1038/mt.2012.26. View

17.

Deconinck A, Rafael J, Skinner J, Brown S, Potter A, METZINGER L . Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997; 90(4):717-27. DOI: 10.1016/s0092-8674(00)80532-2. View

18.

van Deutekom J, Janson A, Ginjaar I, Frankhuizen W, Aartsma-Rus A, Bremmer-Bout M . Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357(26):2677-86. DOI: 10.1056/NEJMoa073108. View

19.

Oliver P, Keays D, Davies K . Behavioural characterisation of the robotic mouse mutant. Behav Brain Res. 2007; 181(2):239-47. DOI: 10.1016/j.bbr.2007.04.012. View

20.

Monaco A, Bertelson C, Moser H, Kunkel L . An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1):90-5. DOI: 10.1016/0888-7543(88)90113-9. View